Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Fidelity National Information Servcs Inc (FIS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Fidelity National Information Servcs Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.73 (market cap $4.49B), while Fidelity National Information Servcs Inc trades at $40.91 (market cap $22.02B). The key difference: Fidelity National Information Servcs Inc is far larger — about 4.9× ACADIA Pharmaceuticals Inc.'s market cap, and Fidelity National Information Servcs Inc pays a 3.94% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | FIS | |
|---|---|---|
Market Cap | $4.49B | $22.02B |
Sector | Health | Technology |
52-Week High | $28.06 | $81.94 |
52-Week Low | $20.06 | $37.72 |
Enterprise Value | $3.69B | $42.41B |
Dividend Yield | — | 3.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
FIS trades at $42.6, up 1.91% today, with a bullish technical signal despite mixed moving averages. The company shows improving fundamentals with 2025 revenue of $10.68B and a net income margin of 23.35%, supported by a low P/E of 8. Recent news highlights strategic wins, including partnerships with Frankfurt International Bank and First Commerce Bank for cloud-native banking solutions, reinforcing its competitive positioning in financial technology.
The outlook is positive with a consensus price target of $55.40, implying significant upside. Key opportunities include continued revenue growth and margin expansion, but risks involve a high debt load and macroeconomic pressures on lending markets. Analyst sentiment is strongly bullish with 58% buy ratings, though investors should monitor execution on debt management and competitive threats.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →
